Trials / Terminated
TerminatedNCT01189019
HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration
High Dose Lucentis for Persistent Pigment Epithelial Detachment in Neovascular Age-related Macular Degeneration - The HiPED Study
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Anne Fung MD · Academic / Other
- Sex
- All
- Age
- 50 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
In this fifth year of anti-VEGF therapy for neovascular AMD, retinal physicians are collecting groups of patients who either do not or only partially respond to anti-VEGF therapy. This study will evaluate the efficacy and safety of 2mg ranibizumab specifically for patients with fibrovascular PEDs that have not resolved following at least 6 consecutive injections of ranibizumab or bevacizumab over the previous 12 months. The investigators hypothesize that the 2mg dose will be able to completely eliminate the persistent PEDS in these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ranibizumab | 2mg intravitreal injection monthly |
| DRUG | ranibizumab | 2mg monthly x 3 doses, then as needed based on recurrence of activity on OCT |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2013-03-01
- Completion
- 2013-03-01
- First posted
- 2010-08-26
- Last updated
- 2016-03-29
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01189019. Inclusion in this directory is not an endorsement.